ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push

ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push

ANI Pharmaceuticals (ANIP) has announced the expansion of its drug Cortrophin (corticotropin) to include the treatment of acute gout flares. The company is deploying a dedicated 90-person sales force to promote this new indication, as investors watch for adoption and spending trends.

The Product

Cortrophin is a formulation of adrenocorticotropic hormone (ACTH) used to treat various inflammatory conditions. It works by stimulating the adrenal glands to produce cortisol, reducing inflammation. This expansion is significant because acute gout flares involve severe pain and inflammation, and some patients may not respond adequately to standard treatments.

Pricing and Availability

ANI Pharmaceuticals has not disclosed pricing details yet, but Cortrophin is expected to be priced as a specialty drug. It will be available by prescription, and the company will focus on reaching rheumatologists and emergency physicians.

Competition

Cortrophin faces competition from established gout flare treatments such as colchicine, NSAIDs, and corticosteroids. However, it may offer an alternative for patients who do not respond to or cannot tolerate these therapies.

Potential Impact on the Company

This expansion represents an opportunity for ANI Pharmaceuticals to boost revenue by targeting the large gout market. Investors will focus on physician adoption rates, spending levels, and any key milestones the company may announce in 2026.